GlassScriptPhysician profile
Rebecca E Barrington
NPI 1538180088
$2,677.98
in general payments reported to CMS, 2019-2025
31 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $289 · 2021: $336 · 2022: $263 · 2023: $46.85 · 2024: $92.66 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,000 · Food and Beverage: $282 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,000.00 |
| Food and Beverage | $282.32 |
| Education | $142.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,302.90 | 2019-2025 | |
| Janssen Biotech, INC. | $320.01 | 2019-2025 | Talvey, Tecvayli, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $170.34 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.00 | 2022 | |
| Puma Biotechnology, INC. | $91.29 | 2020-2025 | |
| Amgen INC. | $66.20 | 2019-2021 | |
| Incyte Corporation | $60.99 | 2020 | |
| Genzyme Corporation | $59.27 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $58.60 | 2022-2025 | Tagrisso |
| Eisai INC. | $37.72 | 2021-2022 | |
| Adc Therapeutics America, INC. | $37.07 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.42 | 2019 | |
| Beigene USA, INC. | $32.78 | 2021 | |
| Jazz Pharmaceuticals INC. | $25.66 | 2021 | |
| Sobi, INC | $25.28 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $23.56 | 2022 | |
| Myriad Genetic Laboratories, INC. | $20.15 | 2021 | |
| Emd Serono, INC. | $18.94 | 2019 | |
| Rigel Pharmaceuticals, INC. | $18.41 | 2020 | |
| Lilly USA, LLC | $18.17 | 2019 | |
| Celgene Corporation | $17.47 | 2024 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Kite Pharma, INC. | $15.70 | 2021 | |
| Genentech USA, INC. | $14.86 | 2022 | |
| Merck Sharp & Dohme LLC | $14.52 | 2019 | |
| Array Biopharma INC | $13.68 | 2019 | |
| Glaxosmithkline, LLC. | $13.65 | 2025 | Jemperli |
| Novartis Pharmaceuticals Corporation | $13.44 | 2022 | |
| Aptevo Therapeutics INC | $11.99 | 2019 | |
| Acrotech Biopharma INC. | $11.97 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Barrington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.